Immunovant’s two investigational product candidates, batoclimab (“IMVT-1401”) and IMVT-1402, are novel, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn). We believe that each of these product candidates has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection.
Read More